Nektar Restructuring Pays Off in Fourth-Quarter Results
This article was originally published in The Pink Sheet Daily
Executive Summary
New Exubera partner sought by mid-year, two more Phase IIs coming with cancer drug, CEO says.
You may also be interested in...
Nektar Seeking New Partner For Exubera As Pfizer Returns Rights
Pfizer pays Nektar $135 million, resolving Exubera contract, and returns rights – providing Nektar finds a partner, firm tells “The Pink Sheet” DAILY.
Nektar/Bayer Agree To Develop Inhaled Amikacin For Hospital-Acquired Pneumonia
Product combining Nektar’s deep-lung delivery technology and amikacin formulation could reach market in 2010-2011 timeframe, Nektar COO tells “The Pink Sheet” DAILY.
Nektar Reorganizes To Position Pegylated, Pulmonary Units For Future Development
Spending cuts amounting to $65 million annually are not driven by lackluster performance of Exubera, CEO Robin maintains.